Common Stock, Shares, Issued of Allogene Therapeutics, Inc. from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Summary
Allogene Therapeutics, Inc. quarterly Common Stock, Shares, Issued in shares history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • Allogene Therapeutics, Inc. Common Stock, Shares, Issued for the quarter ending 31 Dec 2025 was 229,413,523, a 8.1% increase year-over-year.
Source SEC data
View on sec.gov
Common Stock, Shares, Issued, Quarterly (shares)
Common Stock, Shares, Issued, YoY Quarterly Change (%)

Allogene Therapeutics, Inc. Quarterly Common Stock, Shares, Issued (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 229,413,523 +17,202,926 +8.1% 31 Dec 2025 10-K 12 Mar 2026 2025 FY
Q3 2025 223,163,672 +13,663,535 +6.5% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 220,133,876 +11,084,391 +5.3% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 218,598,262 +48,145,295 +28% 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 212,210,597 +43,568,359 +26% 31 Dec 2024 10-K 12 Mar 2026 2025 FY
Q3 2024 209,500,137 +41,324,916 +25% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 209,049,485 +41,915,821 +25% 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 170,452,967 +24,712,634 +17% 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 168,642,238 +24,203,934 +17% 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 168,175,221 +24,143,633 +17% 30 Sep 2023 10-K 14 Mar 2024 2023 FY
Q2 2023 167,133,664 +23,410,493 +16% 30 Jun 2023 10-K 14 Mar 2024 2023 FY
Q1 2023 145,740,333 +2,170,431 +1.5% 31 Mar 2023 10-K 14 Mar 2024 2023 FY
Q4 2022 144,438,304 +1,815,239 +1.3% 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 144,031,588 +1,591,759 +1.1% 30 Sep 2022 10-K 14 Mar 2024 2023 FY
Q2 2022 143,723,171 +1,602,440 +1.1% 30 Jun 2022 10-K 14 Mar 2024 2023 FY
Q1 2022 143,569,902 +2,099,827 +1.5% 31 Mar 2022 10-K 14 Mar 2024 2023 FY
Q4 2021 142,623,065 +2,148,760 +1.5% 31 Dec 2021 10-K/A 14 Mar 2024 2022 FY
Q3 2021 142,439,829 +2,683,990 +1.9% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 142,120,731 +2,887,281 +2.1% 30 Jun 2021 10-Q 04 Aug 2021 2021 Q2
Q1 2021 141,470,075 +16,207,538 +13% 31 Mar 2021 10-Q 05 May 2021 2021 Q1
Q4 2020 140,474,305 +16,206,947 +13% 31 Dec 2020 10-K 23 Feb 2022 2021 FY
Q3 2020 139,755,839 +17,860,360 +15% 30 Sep 2020 10-Q 04 Nov 2020 2020 Q3
Q2 2020 139,233,450 +17,602,172 +14% 30 Jun 2020 10-Q 05 Aug 2020 2020 Q2
Q1 2020 125,262,537 +3,735,217 +3.1% 31 Mar 2020 10-Q 06 May 2020 2020 Q1
Q4 2019 124,267,358 +2,784,687 +2.3% 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 121,895,479 +90,624,906 +290% 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 121,631,278 30 Jun 2019 10-Q 07 Aug 2019 2019 Q2
Q1 2019 121,527,320 31 Mar 2019 10-Q 07 May 2019 2019 Q1
Q4 2018 121,482,671 +95,232,678 +363% 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q3 2018 31,270,573 30 Sep 2018 10-Q 21 Nov 2018 2018 Q3
Q4 2017 26,249,993 31 Dec 2017 10-K 08 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.